Virus like particles are a powerful platform to generate highly immunogenic vaccines, particularly for viruses that are mutating frequently. These particles are made from viral proteins that self-assemble into a structure resembling a virus’s outer shell. Vaccines based on virus like particles for hepatitis B and human papillomavirus are available commercially.
An integrated system of tools for protein expression, purification, and quality control testing can help support efficient and cost-effective virus like particle production on a commercial scale.
Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy